Drachman v. BioDelivery Sciences International, Inc.

CourtCourt of Chancery of Delaware
DecidedAugust 25, 2021
DocketC.A. No. 2019-0728-LWW
StatusPublished

This text of Drachman v. BioDelivery Sciences International, Inc. (Drachman v. BioDelivery Sciences International, Inc.) is published on Counsel Stack Legal Research, covering Court of Chancery of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Drachman v. BioDelivery Sciences International, Inc., (Del. Ct. App. 2021).

Opinion

COURT OF CHANCERY OF THE STATE OF DELAWARE LORI W. WILL LEONARD L. WILLIAMS JUSTICE CENTER VICE CHANCELLOR 500 N. KING STREET, SUITE 11400 WILMINGTON, DELAWARE 19801-3734

Date Submitted: June 17, 2021 Date Decided: August 25, 2021

Brian E. Farnan Blake Rohrbacher Michael J. Farnan Alexander M. Krischik Farnan LLP Richards, Layton & Finger, P.A. 919 North Market Street 920 North King Street Wilmington, Delaware 19801 Wilmington, Delaware 19801

RE: Drachman v. BioDelivery Sciences International, Inc. C.A. No. 2019-0728-LWW

Dear Counsel:

Before me are two motions to compel. The motions—filed by the plaintiffs

on September 30, 2020 and May 6, 2021—both seek production of the same

document. The document is an email chain that was first attached in redacted form

as an exhibit to a brief the defendants filed. The defendants later inadvertently

produced the document in discovery without redactions, clawed it back, and

reproduced it with slightly different redactions. The parties agree that the redacted

portions of the email are subject to the attorney-client privilege. They disagree about

whether certain exceptions to the privilege apply and whether privilege has been

waived. C.A. No. 2019-0728-LWW August 25, 2021 Page 2 of 26

For the reasons explained below, I conclude that neither the so-called Garner

doctrine nor the crime-fraud exception to the attorney-client privilege apply. I also

find that the defendants have not waived privilege by placing the document “at issue”

or using the document as a “sword and shield.” The plaintiffs’ motions to compel

are denied.

I. BACKGROUND1

This litigation concerns two proposals that BioDelivery Sciences

International, Inc.’s Board of Directors submitted for stockholder approval at

BioDelivery’s 2018 annual meeting. The proposals sought to amend BioDelivery’s

certificate of incorporation to declassify its Board and change the voting standard

for uncontested director elections from a plurality standard to a majority voting

standard. Under 8 Del. C. § 242(b), the approval of a majority of the outstanding

stock entitled to vote was required for the proposals to pass. BioDelivery’s proxy

advisor, AST Financial, allegedly advised BioDelivery that the required votes had

been obtained, despite a significant number of broker non-votes. On August 6, 2018,

BioDelivery declared the proposals valid and effectuated the amendments in a filing

1 For a more detailed discussion of the plaintiffs’ allegations, see the court’s previous ruling on the plaintiffs’ Motion for Summary Judgment and Defendants’ Motion to Dismiss. See Dkt. 35. Unless stated otherwise, the facts recited in this decision are based on the undisputed allegations of the Amended Verified Stockholder Derivative and Class Action Complaint (Dkt. 44) and other uncontested documentary exhibits submitted by the parties. C.A. No. 2019-0728-LWW August 25, 2021 Page 3 of 26

with the Delaware Secretary of State, certifying that they were “adopted in

accordance with the provisions of Section 242.”2

On July 31, 2019, the plaintiffs made a pre-suit demand on the Board,

asserting that the vote violated Section 242 and that the amendments were invalid

(the “Demand”). On August 30, 2019, the Board rejected the Demand through its

counsel, Goodwin Procter, LLP.3 The plaintiffs filed this litigation on September

11, 2019. The complaint included three claims: violation of 8 Del. C. § 242; breach

of fiduciary duty; and a declaratory judgment that the amendments were not validly

approved.4 Regarding their second claim, the plaintiffs alleged that:

Defendants breached their fiduciary duties and acted in bad faith by (a) deeming the Two Proposals approved in violation of the DGCL, (b) filing the Amendments with the Delaware Secretary of State, (c) implementing the Amendments and (d) refusing to take appropriate action in response to the Demand.5

Before the defendants responded to the complaint, the plaintiffs moved for

summary judgment.6 On December 6, 2019, the defendants filed a combined brief

in opposition to the plaintiffs’ motion for summary judgment and in support of their

2 Aff. of Alexander M. Krischik (“Krischik Aff.”) Ex. 1 at 7–8 (Dkt. 14). 3 Aff. of Douglas E. Julie (“Julie Aff.”) Ex. I (Dkt. 7). 4 Verified S’holders Class Action Compl. (Dkt. 1). 5 Id. ¶ 86. 6 Dkt. 7. C.A. No. 2019-0728-LWW August 25, 2021 Page 4 of 26

motion to dismiss under Court of Chancery Rule 12(b)(6).7 The defendants attached

to their brief an August 3, 2018 email exchange between Michelle Brown, Director

of Financial Reporting at BioDelivery, and attorneys from Goodwin Procter,

including partner Robert Puopolo.8 The defendants asserted in their brief that the

email demonstrates the Board’s reliance on the advice of AST that the proposals had

passed.9

In the version of the document attached to the defendants’ brief, the email at

the bottom of the chain was redacted except for a heading showing that it was sent

from Brown to Puopolo at 1:12 p.m. and that Herm Cukier (then-CEO of

BioDelivery) and Ernest R. DePaolantonio (BioDelivery’s CFO) were copied.10

Puopolo’s 2:56 p.m. response to Brown was also redacted, other than: “Hi – Herm,

I tried to call so if you have a minute, give me a ring . . . .”11 At 3:30 p.m., Brown

responded, designating her email as “Importance: High”:

7 Dkts. 13, 14. 8 Krischik Aff. Ex. 3. 9 See Defs.’ Opening Br. 24 n.18 (Dkt. 14); Defs.’ Reply Br. 5 n.3 (Dkt. 27). 10 Krischik Aff. Ex. 3. 11 After the defendants inadvertently produced—and subsequently clawed back—the unredacted email discussion, the defendants produced to the plaintiffs a copy of the same email that unredacted the last sentence of Puopolo’s reply to Brown. Compare id., with Pls.’ Mot. to Compel Production of Improperly Clawed-Back Doc. (“Pls.’ Second Mot. to Compel”) Ex. B (Dkt. 69); see infra at 8. C.A. No. 2019-0728-LWW August 25, 2021 Page 5 of 26

I am on the phone with AST and part of the issue is that Broadridge does not deem proposals 1 and 2 under the same standard as proposal 3, which is why there is almost 22M of broker non-votes sitting there for proposals 1 and 2. We internally too were using the same voting method.

However, their proxy department is on the line, and they are still telling me that both proposals 1 and 2 have passed, because we can use the method to divide total voted over proxy shares voted.

Rob, [REDACTED].12

On April 14, 2019, then-Chancellor Bouchard denied the defendants’ motion

to dismiss. Regarding the claim for breach of fiduciary duty, the court found that it

was reasonably conceivable that the directors acted in bad faith because the claim

“is not just about the initial tabulation of votes, but involves the board’s refusal to

take action when the tabulation problem was brought to the board’s attention.”13 The

court drew two inferences from the refusal of the plaintiffs’ pre-suit Demand: “One

is that the board received and relied on bad legal advice in response to plaintiffs’

demand. . . . A second . . . is that the directors just did not care about complying with

12 Krischik Aff. Ex. 3. 13 Mot. to Dismiss Hr’g Tr. and Rulings of the Court (“Tr.”) 53–55 (Apr. 14, 2019) (Dkt. 35). Chancellor Bouchard noted that, “[i]f the complaint merely focused on how the votes were tabulated at the 2018 annual meeting, [he] likely would have a different opinion on the matter.” Id. at 53. The court also denied the plaintiffs’ motion for summary judgment. Id. at 46–47. C.A. No.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Commodity Futures Trading Commission v. Weintraub
471 U.S. 343 (Supreme Court, 1985)
Zirn v. VLI Corp.
621 A.2d 773 (Supreme Court of Delaware, 1993)
Alaska Elec. Pension Fund v. Brown
988 A.2d 412 (Supreme Court of Delaware, 2010)
Grimes v. DSC Communications Corp.
724 A.2d 561 (Court of Chancery of Delaware, 1998)
Ramada Inns, Inc. v. Dow Jones & Co., Inc.
523 A.2d 968 (Superior Court of Delaware, 1986)
Tackett v. State Farm Fire & Casualty Insurance Co.
653 A.2d 254 (Supreme Court of Delaware, 1995)
Princeton Insurance v. Vergano
883 A.2d 44 (Court of Chancery of Delaware, 2005)
In Re Grand Jury Subpoena
745 F.3d 681 (Third Circuit, 2014)
Garner v. Wolfinbarger
430 F.2d 1093 (Fifth Circuit, 1970)

Cite This Page — Counsel Stack

Bluebook (online)
Drachman v. BioDelivery Sciences International, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/drachman-v-biodelivery-sciences-international-inc-delch-2021.